134 related articles for article (PubMed ID: 12860962)
1. Paclitaxel pharmacokinetics, threshold models, and dosing strategies.
Extermann M
J Clin Oncol; 2003 Jul; 21(14):2804-5; author reply 2805-6. PubMed ID: 12860962
[No Abstract] [Full Text] [Related]
2. Paclitaxel pharmacokinetics, threshold models, and dosing strategies.
Sparreboom A; Verweij J
J Clin Oncol; 2003 Jul; 21(14):2803-4; author reply 2805-6. PubMed ID: 12860961
[No Abstract] [Full Text] [Related]
3. A phase I and pharmacokinetic study of paclitaxel poliglumex (XYOTAX), investigating both 3-weekly and 2-weekly schedules.
Boddy AV; Plummer ER; Todd R; Sludden J; Griffin M; Robson L; Cassidy J; Bissett D; Bernareggi A; Verrill MW; Calvert AH
Clin Cancer Res; 2005 Nov; 11(21):7834-40. PubMed ID: 16278406
[TBL] [Abstract][Full Text] [Related]
4. Prospective evaluation of body surface area as a determinant of paclitaxel pharmacokinetics and pharmacodynamics in women with solid tumors: Cancer and Leukemia Group B Study 9763.
Miller AA; Rosner GL; Egorin MJ; Hollis D; Lichtman SM; Ratain MJ
Clin Cancer Res; 2004 Dec; 10(24):8325-31. PubMed ID: 15623609
[TBL] [Abstract][Full Text] [Related]
5. Real-time pharmacokinetics guiding clinical decisions; phase I study of a weekly schedule of liposome encapsulated paclitaxel in patients with solid tumours.
Soepenberg O; Sparreboom A; de Jonge MJ; Planting AS; de Heus G; Loos WJ; Hartman CM; Bowden C; Verweij J
Eur J Cancer; 2004 Mar; 40(5):681-8. PubMed ID: 15010068
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic/pharmacodynamic modeling and simulation of neutropenia during phase I development of liposome-entrapped paclitaxel.
Fetterly GJ; Grasela TH; Sherman JW; Dul JL; Grahn A; Lecomte D; Fiedler-Kelly J; Damjanov N; Fishman M; Kane MP; Rubin EH; Tan AR
Clin Cancer Res; 2008 Sep; 14(18):5856-63. PubMed ID: 18794097
[TBL] [Abstract][Full Text] [Related]
7. Phase I and pharmacokinetic study of AI-850, a novel microparticle hydrophobic drug delivery system for paclitaxel.
Mita AC; Olszanski AJ; Walovitch RC; Perez RP; MacKay K; Tuck DP; Simmons C; Hammond S; Mita MM; Beeram M; Stone AJ; Rowinsky EK; Lewis LD
Clin Cancer Res; 2007 Jun; 13(11):3293-301. PubMed ID: 17545535
[TBL] [Abstract][Full Text] [Related]
8. A simplified premedication schedule for 1-hour paclitaxel administration.
Tsavaris N; Kosmas C; Vadiaka M
J Support Oncol; 2005; 3(1):77-81. PubMed ID: 15724950
[TBL] [Abstract][Full Text] [Related]
9. Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies.
Nyman DW; Campbell KJ; Hersh E; Long K; Richardson K; Trieu V; Desai N; Hawkins MJ; Von Hoff DD
J Clin Oncol; 2005 Nov; 23(31):7785-93. PubMed ID: 16258082
[TBL] [Abstract][Full Text] [Related]
10. Physicochemical stability, pharmacokinetic, and biodistribution evaluation of paclitaxel solid dispersion prepared using supercritical antisolvent process.
Shanmugam S; Park JH; Chi SC; Yong CS; Choi HG; Woo JS
Drug Dev Ind Pharm; 2011 Jun; 37(6):628-37. PubMed ID: 21401339
[TBL] [Abstract][Full Text] [Related]
11. [Paclitaxel].
Omuro Y; Sasaki T
Gan To Kagaku Ryoho; 2001 Oct; 28(10):1357-62. PubMed ID: 11681242
[TBL] [Abstract][Full Text] [Related]
12. Phase 1 study of escalating-dose OncoGel (ReGel/paclitaxel) depot injection, a controlled-release formulation of paclitaxel, for local management of superficial solid tumor lesions.
Vukelja SJ; Anthony SP; Arseneau JC; Berman BS; Cunningham CC; Nemunaitis JJ; Samlowski WE; Fowers KD
Anticancer Drugs; 2007 Mar; 18(3):283-9. PubMed ID: 17264760
[TBL] [Abstract][Full Text] [Related]
13. Feasibility study and pharmacokinetics of low-dose paclitaxel in cancer patients with severe hepatic dysfunction.
Briasoulis E; Karavasilis V; Tzamakou E; Piperidou C; Soulti K; Pavlidis N
Anticancer Drugs; 2006 Nov; 17(10):1219-22. PubMed ID: 17075322
[TBL] [Abstract][Full Text] [Related]
14. Association of Paclitaxel pharmacokinetics with the development of peripheral neuropathy in patients with advanced cancer.
Mielke S; Sparreboom A; Steinberg SM; Gelderblom H; Unger C; Behringer D; Mross K
Clin Cancer Res; 2005 Jul; 11(13):4843-50. PubMed ID: 16000582
[TBL] [Abstract][Full Text] [Related]
15. A pharmacokinetic and safety study of a novel polymeric paclitaxel formulation for oral application.
Veltkamp SA; Alderden-Los C; Sharma A; Rosing H; Beijnen JH; Schellens JH
Cancer Chemother Pharmacol; 2007 Jan; 59(1):43-50. PubMed ID: 16680462
[TBL] [Abstract][Full Text] [Related]
16. Altered pharmacokinetics of paclitaxel by the concomitant use of morin in rats.
Choi BC; Choi JS; Han HK
Int J Pharm; 2006 Oct; 323(1-2):81-5. PubMed ID: 16806758
[TBL] [Abstract][Full Text] [Related]
17. Flat dose (175 mg/weekly) paclitaxel: pharmacokinetics and clinical implications.
Mross K; Holländer N; Unger C; Massing U
Int J Clin Pharmacol Ther; 2005 Dec; 43(12):601-2. PubMed ID: 16372534
[No Abstract] [Full Text] [Related]
18. Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol).
Sparreboom A; Scripture CD; Trieu V; Williams PJ; De T; Yang A; Beals B; Figg WD; Hawkins M; Desai N
Clin Cancer Res; 2005 Jun; 11(11):4136-43. PubMed ID: 15930349
[TBL] [Abstract][Full Text] [Related]
19. Enhanced absorption and tissue distribution of paclitaxel following oral administration of DHP 107, a novel mucoadhesive lipid dosage form.
Shin BS; Kim HJ; Hong SH; Lee JB; Hwang SW; Lee MH; Yoo SD
Cancer Chemother Pharmacol; 2009 Jun; 64(1):87-94. PubMed ID: 18941747
[TBL] [Abstract][Full Text] [Related]
20. Phase I and pharmacokinetic study of BMS-188797, a new taxane analog, administered on a weekly schedule in patients with advanced malignancies.
Advani R; Fisher GA; Lum BL; Jambalos C; Cho CD; Cohen M; Gollerkeri A; Sikic BI
Clin Cancer Res; 2003 Nov; 9(14):5187-94. PubMed ID: 14613998
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]